Full Breakdown
Study Links Cefepime to Higher All-Cause Mortality in Hospitalized Patients
By Drooid · · How we work
Core Findings
A meta-analysis of 110 randomized clinical trials involving more than 22,000 patients found that the broad-spectrum antibiotic cefepime was associated with a modestly higher risk of death from any cause compared with other beta-lactam antibiotics. Across all trials, 778 deaths occurred among 11,726 patients who received cefepime (6.6%), versus a 6.2% death rate among those given alternative agents. The Bayesian analysis yielded a 94.4% probability that cefepime increased all-cause mortality, rising to 98.6% when limited to 73 peer-reviewed published trials. The association was strongest in adult patients, particularly those treated for febrile neutropenia.
Study Scope and Methodology
The investigation, published in *JAMA Network Open*, combined data from trials that enrolled both adults and children with conditions such as pneumonia, severe bacterial infections, urinary-tract infections, meningitis, and febrile neutropenia. Researchers evaluated deaths occurring within roughly 30 days of treatment. Because the included trials varied in design, patient populations, dosing regimens, and comparator antibiotics—and some dated back several decades—the analysis reflects an aggregation of heterogeneous studies rather than a single uniform trial.
Expert Interpretation
Dr. Marc Siegel, a senior medical analyst, emphasized the difficulty of separating the effects of cefepime from the underlying severity of febrile neutropenia, noting that the condition itself is a major cause of death in this group. He suggested that both under-dosing (potentially ineffective infection control) and over-dosing (risk of neurotoxicity) might drive poorer outcomes, and proposed that artificial-intelligence tools could help refine dosing strategies.
Clinical Implications and Next Steps
The study’s authors did not call for discontinuation of cefepime but urged additional guidance and research to clarify optimal dosing, especially for older adults and patients with renal impairment who are at higher risk of adverse neurologic effects such as confusion, decreased consciousness, or seizures. Future investigations may focus on pharmacokinetic monitoring and individualized dosing protocols to balance antimicrobial efficacy against toxicity.
Verbatim Quotes
- “In this case, it correctly pointed out that febrile neutropenia (low white blood cell count with a fever) is itself a big cause of death in this population, making it often difficult to determine if the treatment (cefepime) decreases or possibly increases this risk,” — Dr. Marc Siegel, Fox News senior medical analyst